

IVIG Comparison Chart

	Flebogamma® 5% DIF	Gammagard S/D	Gamunex	Gammagard Liquid	Carimune-NF	Privigen	Octagam
Manufacturer	Grifols	Baxter	Talecris	Baxter	CSL-Behring	CSL-Behring	Octapharma
pH (after reconstitution)	5.0-6.0	6.8	4.0-4.5	4.6-5.1	6.6	4.8	5.1-6.0
Concentration	5%	5% and 10%	10%	10 %	3, 6, 9 or 12%	10%	5%
IgA Content	< 3 µg/mL (n=3)	2.2 µg/mL	46 µg /mL	Averages 37 µg/mL	720 µg/mL	<25µg/mL	<200 µg/mL
% IgG	99.5% + 0.2 (n=3)	>90%	98%	>98%	>96%	>98%	>96%
Na Content (at 5% concentration)	< 3.2 mmol/L	0.85%	Trace	Non-detectable	< 20 mg NaCL/gm protein	Trace	<30 mmol/L
Diluent	NA	Sterile Water	NA	NA	Sterile Water, 5% Dextrose or 0.9% NaCL	NA	NA
Osmolality (mOsm/L)	240-370	5% - 636 10% - 1250	258	240-300	SW- 192-768 5% D- 444-1020 0.9 NaCL- 498-1074	320	310-380
Initial Infusion Rate (consult package insert for full prescribing information)	Initial rate of 0.01 mL/kg body weight/minute, if well tolerated during the first 30 minutes, can be gradually increased to a max of 0.1 mL/kg/minute	5% solution – start at 0.5 mL/kg/hr, patients who tolerate a 5% solution up to 4mL/kg/hr can be infused w/ a 10% solution starting at 0.5mL/kg/hr	Initial rate of 0.01mL/kg/min for 30 minutes if tolerated gradually increase to rate of 0.08mL/kg/min	Initial rate of 0.5mL/kg/hr when well tolerated is gradually increased every 30 minutes to a max rate of 5.0mL/kg/hr	See calculations in package insert	Initial rate of 0.005mL/kg/min gradually increase to 0.04mL/kg/min	Initial rate of 0.001mL/kg/min Max rate of 0.07mL/kg/min
Sugar Content	5% D-Sorbitol	2% Glucose	No sugar added	No added sugars	1.67 gm sucrose/gm	No sugar added	100mg/ml maltose
Form	Liquid	Lyophilized	Liquid	Liquid	Lyophilized	Liquid	Liquid
Storage Requirements	24 months 2-25°C (36-77°F)	24 months room temperature not to exceed 25°C (77°F)	36 months refrigerated temperature 2-8°C (36-46°F) Up to 6 months at 25°C (77°F)	36months at refrigerated temperature 2-8°C (36-46°F) Up to 9 months at 25°C (77°F) within 24 months of manufacture	24 months 2-25°C (36-77°F)	24 months 2-25°C (36-77°F)	24 months 2-25°C (36-77°F)
Flushing Compatibility	N/A	Saline or dextrose	Flush with Dextrose-incompatible with Saline	Saline or dextrose	Saline or dextrose	Saline or dextrose	Saline or Dextrose

rev 4/08

1-866-44-BIORX
1-866-442-4679
Fax: 513-792-3838
Toll Free Fax: 1-877-588-8470





BioRx is a national specialty pharmacy and wholesale distributor of IVIG and related medications

Because each practice environment is different, BioRx offers program alternatives that can be tailored to your specific requirements.

Contact your BioRx representative today to learn more about how our in-office and home IV therapy programs may benefit you.

Comprehensive In-Office IV Therapy Program

- Comprehensive in-office IV therapy program
- Highly customized programs, whether you are in the early planning stages or have a high-volume infusion suite already running
- Programs available for both high-volume and low-volume practices
- Reimbursement services or consultation
- Infusion nurse staffing options
- Revenue and income modeling specific to your practice
- Pharmaceutical procurement programs
- Clinical procedures, oversight, and advice
- Infusion device and supply management
- Infusion suite design and implementation
- Wide range of medication programs

Home IVIG

Our support capabilities include:

- Infusion nursing coordination
- Reimbursement & billing services
- Patient education programs
- Various 3rd party payor experience
- Availability 24 hours a day, 365 days a year
- Experienced clinicians
- Lot tracking and re-call notice procedure



1-866-44-BIORX

1-866-442-4679

Fax: 513-792-3838

Toll Free Fax: 1-877-588-8470

Peace of Mind

Careful screening for product contraindications and reducing side effects is a cornerstone of our clinical assessment process. Screening patients help IVIG prescribers deliver therapy with confidence.

IVIG products are different

BioRx utilizes a comprehensive procedure with each patient prior to treatment for appropriately selecting an IVIG brand and screening for potential adverse drug reactions.